Pilot Trial of Temsirolimus and Perifosine in Recurrent/Progressive Malignant Gliomas
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2019
Price : $35 *
At a glance
- Drugs Perifosine (Primary) ; Temsirolimus (Primary)
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- 22 Apr 2019 Planned End Date changed from 1 Dec 2016 to 31 Aug 2019.
- 07 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Jul 2015 According to the ClinicalTrials.gov record, planned number of patients changed from 17 to 22.